Lexeo Therapeutics (LXEO) Competitors $6.28 +0.24 (+3.97%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LXEO vs. PAHC, COGT, NUVB, AVBP, IMTX, QURE, REPL, ETNB, PLRX, and RLAYShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Phibro Animal Health (PAHC), Cogent Biosciences (COGT), Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), Immatics (IMTX), uniQure (QURE), Replimune Group (REPL), 89bio (ETNB), Pliant Therapeutics (PLRX), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. Phibro Animal Health Cogent Biosciences Nuvation Bio ArriVent BioPharma Immatics uniQure Replimune Group 89bio Pliant Therapeutics Relay Therapeutics Lexeo Therapeutics (NASDAQ:LXEO) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Does the MarketBeat Community favor LXEO or PAHC? Phibro Animal Health received 291 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 59.85% of users gave Phibro Animal Health an outperform vote. CompanyUnderperformOutperformLexeo TherapeuticsOutperform Votes19100.00% Underperform VotesNo VotesPhibro Animal HealthOutperform Votes31059.85% Underperform Votes20840.15% Is LXEO or PAHC more profitable? Phibro Animal Health has a net margin of 1.67% compared to Lexeo Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 21.59% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -57.66% -48.18% Phibro Animal Health 1.67%21.59%5.85% Do institutionals and insiders believe in LXEO or PAHC? 60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts prefer LXEO or PAHC? Lexeo Therapeutics presently has a consensus target price of $23.80, suggesting a potential upside of 278.98%. Phibro Animal Health has a consensus target price of $20.50, suggesting a potential downside of 5.49%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Lexeo Therapeutics is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Phibro Animal Health 2 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the media refer more to LXEO or PAHC? In the previous week, Phibro Animal Health had 5 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 9 mentions for Phibro Animal Health and 4 mentions for Lexeo Therapeutics. Phibro Animal Health's average media sentiment score of 0.79 beat Lexeo Therapeutics' score of 0.37 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phibro Animal Health 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, LXEO or PAHC? Phibro Animal Health has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo Therapeutics$650K319.47-$66.39M-$3.16-1.99Phibro Animal Health$1.05B0.84$2.42M$0.4350.44 SummaryPhibro Animal Health beats Lexeo Therapeutics on 12 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$199.72M$2.94B$5.13B$9.07BDividend YieldN/A1.90%5.08%4.23%P/E Ratio-1.9946.7389.5817.17Price / Sales319.47415.011,116.12116.95Price / CashN/A182.1042.8237.86Price / Book1.473.894.774.78Net Income-$66.39M-$42.21M$120.15M$225.60M7 Day Performance-8.72%-2.15%-1.92%-1.23%1 Month Performance1.29%4.20%11.47%3.36%1 Year Performance-57.16%18.39%30.54%16.60% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics2.7893 of 5 stars$6.28+4.0%$23.80+279.0%-54.8%$199.72M$650,000.00-1.9958News CoverageGap DownHigh Trading VolumePAHCPhibro Animal Health4.1342 of 5 stars$22.69+0.1%$19.00-16.3%+89.6%$919.01M$1.05B52.561,940Analyst ForecastCOGTCogent Biosciences1.9533 of 5 stars$8.30+1.8%$14.83+78.7%+51.9%$916.82MN/A-3.2980NUVBNuvation Bio2.3903 of 5 stars$2.71+3.8%$6.60+143.5%+90.1%$912.11MN/A0.0060News CoverageGap DownAVBPArriVent BioPharma0.9628 of 5 stars$26.78+0.2%$36.80+37.4%N/A$902.41MN/A0.0040News CoveragePositive NewsIMTXImmatics1.4116 of 5 stars$7.31+1.4%$16.67+128.0%-25.3%$872.49M$115.50M-10.92260QUREuniQure3.5116 of 5 stars$17.56+14.0%$32.13+82.9%+172.3%$855.93M$28.59M-3.36500Analyst ForecastREPLReplimune Group4.5424 of 5 stars$12.29-2.1%$17.29+40.6%+67.4%$840.88MN/A-4.11210Insider TradeETNB89bio1.78 of 5 stars$7.87+2.3%$30.33+285.4%-22.4%$835.21MN/A-2.6440News CoveragePositive NewsPLRXPliant Therapeutics3.3626 of 5 stars$13.69+2.9%$40.50+195.8%-19.0%$833.04M$1.58M0.0090RLAYRelay Therapeutics2.2525 of 5 stars$4.86+3.2%$20.50+321.8%-60.4%$813.47M$25.55M-1.80304Insider Trade Related Companies and Tools Related Companies Phibro Animal Health Competitors Cogent Biosciences Competitors Nuvation Bio Competitors ArriVent BioPharma Competitors Immatics Competitors uniQure Competitors Replimune Group Competitors 89bio Competitors Pliant Therapeutics Competitors Relay Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LXEO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
